Physician profile
Lawrence Schwartz
NPI 1053450403
$2,043.78
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $914.66 | 2019 | |
| Glaxosmithkline, LLC. | $348.84 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $230.23 | 2019 | |
| Insmed, INC. | $176.38 | 2019 | |
| Janssen Pharmaceuticals, INC | $65.44 | 2019 | |
| Amarin Pharma, INC. | $46.30 | 2019 | |
| Sanofi Pasteur INC. | $37.48 | 2019 | |
| Advanced Respiratory, INC | $30.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $24.81 | 2019 | |
| Astellas Pharma US INC | $24.63 | 2019 | |
| Dynavax Technologies Corporation | $23.24 | 2019 | |
| Melinta Therapeutics, LLC | $21.82 | 2019 | |
| Lilly USA, LLC | $21.50 | 2019 | |
| Janssen Biotech, INC. | $19.65 | 2019 | |
| Philips North America LLC | $18.35 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $16.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.75 | 2019 | |
| Allergan, INC. | $11.20 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Schwartz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.